LGLeonid Gibiansky

Leonid Gibiansky

*This is an algorithmically generated author record based on publicly available information.

Leonid Gibiansky has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL

    by Candice Jamois, David C. Turner, Leonid Gibiansky, Feifei Li, Jean‐Francois Menuet, Leonardo Roque Pereira, Linda Lundberg, Elena Guerini, David J. Carlile, James Relf, et al.

    The recent surge in T‐cell‐engaging and chimeric antigen receptor (CAR) T‐cell therapies is changing the landscape of cancer therapy. Cytokine release syndrome (CRS) is a systemic inflammatory response syndrome that is a well‐known complication of these therapies, of which interleukin‐6 (IL‐6) is a key mediator. Tocilizumab, an IL‐6 receptor (IL‐6R) antagonist, is approved for the management of CAR T‐cell therapy‐induced CRS in adults and in pediatric patients aged ≥ 2 years old. However, the approved dosing schedule was not based on IL‐6R occupancy and may not be the most suitable schedule for T‐cell‐engaging therapies such as bispecific antibodies (bsAb) due to key differences in the levels of released IL‐6, the clinical symptomatology of CRS, and the pharmacology of tocilizumab across settings. In this study, we adapted a previously developed tocilizumab and soluble IL‐6R (sIL‐6R) population pharmacokinetic model to describe and predict tocilizumab concentrations and sIL‐6R occupancy over time in patients with anti‐CD20 bsAb‐induced CRS following tocilizumab dosing. Using this model, which incorporates target binding and receptor occupancy, we propose a new tocilizumab dosing regimen that is based on quantitative clinical pharmacology, cytokine analyses, and clinical practice patterns in patients with relapsed/refractory B‐cell non‐Hodgkin's lymphoma (R/R B‐NHL) treated with the anti‐CD20 bsAb mosunetuzumab or glofitamab. This schedule (up to two 8 mg/kg intravenous tocilizumab doses per CRS event at least 8 hours apart and a maximum of three doses in 6 weeks) can be used to effectively manage acute CRS induced by anti‐CD20 bsAb in patients with R/R B‐NHL.


  • Open Access

    Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma

    by Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Matthew Putnins, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu

    Epcoritamab is a CD3xCD20 bispecific antibody that activates T cells to kill CD20‐expressing B cells. Epcoritamab is approved for the treatment of adults with different types of relapsed or refractory lymphoma in various geographies, including the United States, Europe, and Japan. Epcoritamab demonstrated an overall response rate of 63%, a complete response rate of 39%, and manageable safety with the approved dosing regimen (0.16‐mg and 0.8‐mg step‐up doses and 48‐mg full dose, with dosing every week in cycles 1–3, every 2 weeks in cycles 4–9, and every 4 weeks in cycles ≥ 10) in patients with relapsed or refractory large B‐cell lymphoma from the phase 1/2 EPCORE® NHL‐1 trial expansion through January 31, 2022. Exposure–efficacy analyses including the EPCORE NHL‐1 and EPCORE NHL‐3 trials revealed that higher exposure was associated with a higher overall response rate, complete response rate, progression‐free survival, and overall survival. A potential plateau of efficacy was observed at 48 mg or above. The exposure–safety analyses of these trials did not identify any safety concerns with the approved dosing regimen. No associations were detected between exposure and safety endpoints. The step‐up doses were clinically active and helped mitigate cytokine release syndrome risk at the subsequent full doses. Most initial responses (94%) were observed during the weekly dosing period, and most responders with large B‐cell lymphoma maintained or improved their response during every 2 weeks and every 4 weeks dosing. Overall, these analyses support the approved single‐agent epcoritamab 0.16/0.8/48‐mg dosing regimen in relapsed or refractory large B‐cell lymphoma.


  • Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies

    by Leonid Gibiansky, Ekaterina Gibiansky

    Pharmacokinetic modeling of monoclonal antibodies (mAbs) with non-linear binding is based on equations of the target-mediated drug disposition (Mager and Jusko, J Pharmacokinet Pharmacodyn 28:507–532, 2001). These equations demonstrated their utility in countless examples and drug development programs. The model assumes that the mAb drug and the target have only one binding site each while, in reality, most antibodies have two binding sites. Thus, the currently used model does not correspond to the biological process that it aims to describe. The correct mechanistic model should take into account both binding sites. We investigated, using simulations, whether this discrepancy is important and when it is advisable to use a model with correct stoichiometric 2-to-1 ratio. We show that for soluble targets when elimination rate of the drug-target complex is comparable with the elimination rate of the drug or lower, and when measurements of both total drug and total target concentrations are available, the model with 1-to-1 (monovalent) binding cannot describe data simulated from the model with 2-to-1 (bivalent) binding. In these cases, models with correct stoichiometric assumptions may be necessary for an adequate description of the observed data. Also, a model with allosteric binding that encompasses both 2-to-1 and 1-to-1 binding models as particular cases was proposed and applied. It was shown to be identifiable given the detailed concentration data of total drug and total target.


  • Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site

    by Leonid Gibiansky, Chee M. Ng, Ekaterina Gibiansky

    The paper extended the TMDD model to drugs with more than two (N > 2) identical binding sites (N-to-one TMDD). The quasi-steady-state (N-to-one QSS), quasi-equilibrium (N-to-one QE), irreversible binding (N-to-one IB), and Michaelis–Menten (N-to-one MM) approximations of the model were derived. To illustrate properties of new equations and approximations, N = 4 case was investigated numerically. Using simulations, the N-to-one QSS approximation was compared with the full N-to-one TMDD model. As expected, and similarly to the standard TMDD for monoclonal antibodies (mAb), N-to-one QSS predictions were nearly identical to N-to-one TMDD predictions, except for times of fast changes following initiation of dosing, when equilibrium has not yet been reached. Predictions for mAbs with soluble targets (slow elimination of the complex) were simulated from the full 4-to-one TMDD model and were fitted to the 4-to-one TMDD model and to its QSS approximation. It was demonstrated that the 4-to-one QSS model provided nearly identical description of not only the observed (simulated) total drug and total target concentrations, but also unobserved concentrations of the free drug, free target, and drug-target complexes. For mAb with a membrane-bound target, the 4-to-one MM approximation adequately described the data. The 4-to-one QSS approximation converged 8 times faster than the full 4-to-one TMDD.


  • Open Access

    Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

    by Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R. Flowers, Laurie H. Sehn, Qi Liu, Priya Agarwal, Michael Z. Liao, Randall Dere, Calvin Lee, et al.

    Polatuzumab vedotin is a CD79b‐directed antibody–drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHP) as first‐line treatment of diffuse large B‐cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure–response (ER) analysis, were performed. The popPK analysis showed no clinically meaningful relationship between cycle 6 (C6) antibody‐conjugated (acMMAE)/unconjugated MMAE area under the concentration–time curve (AUC) or maximum concentration, and weight, sex, ethnicity, region, mild or moderate renal impairment, mild hepatic impairment, or other patient and disease characteristics. In the ER analysis, C6 acMMAE AUC was significantly associated with longer progression‐free and event‐free survival (both p = 0.01). An increase of <50% in acMMAE/unconjugated MMAE exposure did not lead to a clinically meaningful increase in adverse events of special interest. ER data and the benefit–risk profile support the use of polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R‐CHP for six cycles in patients with previously untreated DLBCL.


  • Open Access

    Systemic exposures of gantenerumab: An integrated population pharmacokinetics (popPK) analysis across multiple clinical studies

    by Dietmar Schwab, Sebastien Jolivet, Leonid Gibiansky, Dominik Lott

    Background: Characterization of gantenerumab systemic exposure is important to inform dose selection and understand the factors that influence pharmacokinetics (PK), such as participant‐ or study‐specific characteristics, and the safety and efficacy of gantenerumab treatment.Method: Gantenerumab systemic PK following subcutaneous administration was investigated in multiple clinical studies, including single‐dose studies in healthy participants with dense PK sampling and multiple‐dose studies in participants living with AD (pwAD) with sparse PK sampling. An integrated population PK (popPK) analysis was conducted across six single‐dose studies in healthy participants and seven multiple‐dose studies in pwAD using nonlinear mixed‐effects modelling in NONMEM v7.2. The studies in pwAD included GRADUATE I and II (NCT03444870; NCT03443973), GRADUATION (NCT04592341), and the legacy studies SCarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) including their open‐label extensions. In total, 23,200 observations from 3,053 participants were available for analysis. Covariate assessments included demographic characteristics, laboratory values, disease status, concomitant medication, and study‐specific factors.Result: A robust popPK model was established incorporating data from multiple clinical studies with diverse titration and dosing regimens. Main factors identified as influencing exposure were body weight, serum albumin, drug substance generation, and Asian race. Moderate variability at steady‐state (AUCss) was observed, as determined by a coefficient of variation of 22.4% in clearance. Steady‐state exposure in the GRADUATE and GRADUATION studies was slightly higher than expected and within a comparable range versus the legacy studies (see figure). Dosing frequency had no impact on average plasma exposure and a minor impact on minimum and maximum plasma concentrations at steady‐state. The ratio of the plasma concentration–time profile for dosing every week and every 2 weeks was within a 0.8 to 1.25 margin. Low immunogenicity was observed, with 4.8% of the GRADUATE participants being ADA‐positive. The impact of ADAs on exposure was small.Conclusion: Systemic exposure of gantenerumab was well characterized in a popPK analysis. Participants in the GRADUATE, GRADUATION and legacy studies had comparable exposures, with a minor impact of dosing frequency. The lower amyloid removal reported in the GRADUATE studies versus the legacy studies cannot be explained by differences in PK.


  • Open Access

    Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

    by Ellen Q. Wang, Nitin Kaila, David Plowchalk, Leonid Gibiansky, Carla Yunis, Kevin Sweeney

    We sought to characterize the population pharmacokinetic/pharmacodynamic (PK/PD) relationship of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody that binds to secreted human proprotein convertase subtilisin kexin type 9 (PCSK9), using data derived from 16 phase I, II, and III clinical studies (36,066 bococizumab observations, 46,790 low‐density lipoprotein cholesterol [LDL‐C] measurements, 3499 participants). A two‐compartment disposition model with parallel linear and Michaelis–Menten elimination and an indirect response model was used to characterize the population PK and LDL‐C response of bococizumab. Potential model parameters and covariate relationships were explored, and visual predictive checks were used for model assessment and validation. Key covariates included the effect of anti‐drug antibodies (ADAs) on exposure through impact on clearance and bioavailability; impact of statins on bococizumab elimination (maximal rate of metabolism); and impact of statins, Asian race, and male sex on LDL‐C efficacy (maximum effect). ADAs and neutralizing ADAs did not have additional effects on LDL‐C beyond the influence on bococizumab exposure. In conclusion, the population PK/PD model adequately describes bococizumab concentration and LDL‐C efficacy. The covariate effects are consistent with the presumed mechanism of action of PCSK9 inhibitors. With increasing availability of antibody‐based therapeutics, improved understanding of the effect of ADAs and statins on bococizumab PK/PD adds to the literature and enhances our pharmacological understanding of how immunogenicity and concomitant medications may impact the PK/PD of biotherapeutics.


  • Open Access

    Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors

    by Chaitali Passey, Jenna Voellinger, Leonid Gibiansky, Rudy Gunawan, Leonardo Nicacio, Ibrahima Soumaoro, William D. Hanley, Helen Winter, Manish Gupta

    The antibody‐drug conjugate (ADC) tisotumab vedotin (TV) received accelerated approval from the US Food and Drug Administration for treatment of adults with recurrent or metastatic cervical cancer (r/mCC) with disease progression on or after chemotherapy. A population pharmacokinetic (PK) model, developed using dosing data from four clinical TV studies, was used to estimate individual exposure and explore safety and efficacy exposure‐response (ER) relationships. Because PK analysis showed no appreciable accumulation of TV and monomethyl auristatin E (MMAE) with repeated dosing, cycle 1 exposure metrics and predicted average concentrations from time zero until end of the cycle in which an event occurred (CavgLast) were used for ER analyses. The probability of achieving objective response increased significantly as the ADC cycle 1 maximum serum concentration (Cmax) increased. The probability of treatment‐related adverse events (AEs) leading to dose modification increased significantly as ADC cycle 1 area under the concentration‐time curve (AUC) increased. Number of grade 2+ ocular AEs increased significantly as ADC cycle 1 AUC, Cmax, and ADC CavgLast increased. MMAE cycle 1 AUC predicted risk of serious treatment‐related AEs. The relationship between ADC exposure and efficacy end points suggests ADC treatment was associated with clinically meaningful response across the observed exposures; greater exposure was associated with increased efficacy. The relationship between ADC and MMAE exposure and safety end points suggests increased exposure was associated with increased AE risk. These results align with clinical findings showing TV 2 mg/kg (≤200 mg for patients ≥100 kg) every 3 weeks is efficacious and tolerable for patients with r/mCC.


  • Open Access

    Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

    by Leonid Gibiansky, Chaitali Passey, Jenna Voellinger, Rudy Gunawan, William D. Hanley, Manish Gupta, Helen Winter

    Tisotumab vedotin is an investigational antibody–drug conjugate (ADC) for treatment of solid tumors expressing tissue factor with accelerated approval from the US Food and Drug Administration for treatment of recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. This study describes development of a population pharmacokinetic (PK) model to assess the PK profile of tisotumab vedotin and microtubule‐disrupting agent monomethyl auristatin E (MMAE) using data from 399 patients with solid tumors across four phase I/II trials. The ADC–MMAE model describes ADC and MMAE concentrations following intravenous administration of tisotumab vedotin. This four‐compartment model comprises a two‐compartment ADC model with parallel linear and Michaelis–Menten elimination, a delay compartment, and a one‐compartment MMAE model. Nonspecific linear clearance of ADC was 1.42 L/day, central volume of distribution (Vc) was 3.10 L, and median terminal half‐life of ADC was 4.04 days. Apparent clearance of MMAE was 42.8 L/day, and apparent volume of distribution was 2.09 L. Terminal slope of the MMAE concentration–time curve was defined by the delay compartment rate with a half‐life of 2.56 days. Patients with higher body weight and lower albumin concentration had faster ADC clearance. Male patients and those with higher body weight and lower albumin concentration had higher Vc. Body weight was the most influential covariate influencing distribution and elimination of ADC and MMAE, thus supporting weight‐based dosing of tisotumab vedotin. Presence of antidrug antibodies (detected in 3.3% of patients) did not affect key PK parameters or exposures for ADC and MMAE.


  • Open Access

    Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization

    by Stefan Sturm, Annabelle Lemenuel‐Diot, Kashyap Patel, Leonid Gibiansky, Rajinder Bhardwaj, Patrick F. Smith, Steve Dang, Elke Zwanziger, Clare Nasmyth‐Miller, Patanjali Ravva

    Aim Pharmacologic effects were analysed to determine a dose recommendation for oseltamivir in immunocompromised (IC) adults with influenza. Methods Quantitative clinical pharmacology methods were applied to data from 160 adult IC patients (aged 18-78 years) from two studies (NV20234, 150 patients; NV25118, 10 patients) who received oseltamivir 75-200 mg twice daily for up to 10 days. An established population-pharmacokinetic (PK) model with additional effects on oseltamivir and oseltamivir carboxylate (OC) clearance described the PK characteristics of oseltamivir in IC patients versus otherwise healthy (OwH) patients from previous clinical trials. Estimated PK parameters were used to evaluate exposure-response relationships for virologic endpoints (time to cessation of viral shedding, viral load measures and treatment-emergent resistance). A drug-disease model characterized the viral kinetics of influenza accounting for the effect of OC on viral production. Results Oseltamivir clearance was 32.5% lower (95% confidence interval [CI], 26.1-38.8) and OC clearance was 33.7% lower (95% CI, 23.2-44.1) in IC versus OwH patients. No notable exposure-response relationships were identified for exposures higher than those achieved after conventional dose oseltamivir 75 mg, which appeared to be close to the maximum effect of oseltamivir. Simulations of the drug-disease model predicted that initiating treatment within 48 hours of symptom onset had maximum impact, and a treatment duration of 10 days was favourable over 3-5 days to limit viral rebound. Conclusions Our findings support the use of conventional-dose oseltamivir 75 mg twice daily for 10 days in the treatment of IC adult patients with influenza.